Overview of Duofer Fol

Property	Description
Active ingredients	Ferrous Fumarate, Ferrous Gluconate, Folic Acid, Sodium Ascorbate
Form	Film-coated tablets, Capsules
Pharmacological class	Antianemic Agent (Hematopoietic Agent)
Common use	Treatment and prevention of concurrent Iron and Folate deficiency
Origin	Synthetic and Derived Nutrient Combination

What Type of Medicine Is Duofer Fol?

Duofer Fol is a specialized combination medicine, clinically recognized as an Antianemic agent, which falls within the broader category of hematopoietic agents. It is an oral preparation, commonly supplied as film-coated tablets or capsules, blending synthetic chemical components with essential vitamins. Unlike simple dietary supplements, this formulation is engineered for therapeutic use, providing iron and folic acid to address specific deficiencies associated with compromised blood production.

The medicine's identity is defined by its multi-component structure, utilizing the simultaneous delivery of four key constituents to address co-existing nutritional shortfalls that disrupt the body’s ability to manufacture red blood cells. This preparation is often recommended for patient groups, such as pregnant women, who experience an increased requirement for both iron and folic acid.

Composition: The Role of Dual Iron and Folic Acid

The core active ingredients in Duofer Fol are the two iron salts, Ferrous Fumarate and Ferrous Gluconate, combined with Folic Acid (Vitamin B9) and Sodium Ascorbate (Vitamin C). The presence of both Ferrous Fumarate and Ferrous Gluconate is a differentiating factor, providing a dual source of bivalent iron (Fe^2+), the biologically relevant form for systemic utilization.

This specific formulation is highly functional: the Sodium Ascorbate is critical for enhancing iron absorption by preserving the iron in its reduced, readily absorbable state. Folic Acid is simultaneously provided as a vital cofactor required for the proper maturation of red blood cell precursors, ensuring a comprehensive approach to correcting deficiencies.

General Purpose: Why Duofer Fol is Recommended

The overall therapeutic purpose of Duofer Fol is the prevention and treatment of conditions arising from a combined deficit of iron deficiency and folate deficiency. Iron preparations are fundamentally utilized to address a lower-than-normal number of red blood cells when dietary intake alone is insufficient. By supplying the necessary nutrient reserves for robust hemoglobin synthesis and red blood cell production, the preparation helps to maintain effective oxygen delivery throughout the body.

What side effects are possible with Duofer Fol?

Possible side effects and safety information

The safety profile of this medicine, which combines iron salts and Folic Acid, is primarily defined by its effects on the digestive system, as documented in official regulatory labeling.

Adverse Reaction Classification

The most frequently classified adverse reactions for the iron components are related to Gastrointestinal disorders.

Frequency Classification	Examples of Documented Effects
Common	Nausea, vomiting, heartburn, diarrhea, and constipation.
Expected	The passage of black or dark stools, a common and generally harmless characteristic of oral iron therapy.
Rare	Allergic reactions, including skin rash, hives, and itching.

Serious Safety Considerations

Regulatory safety information outlines the risk of severe, though rare, adverse reactions. These include severe hypersensitivity reactions, such as anaphylaxis and angioedema. Acute signs of severe toxicity or overdose may include vomiting blood or passing bloody or tarry stools. Accidental overdose of any iron-containing product is a significant safety concern and is cited as a leading cause of fatal poisoning in young children.

Safety Restrictions and Limitations

Specific safety restrictions relate to certain patient populations and pre-existing conditions. The medicine is contraindicated in individuals with established conditions of iron overload (e.g., hemochromatosis). Furthermore, due to the Folic Acid component, it must not be used as the sole agent to treat a Vitamin B12 deficiency (pernicious anemia), as this could mask the anemia while allowing irreversible neurological damage to advance. Caution is also advised in patients with existing gastrointestinal conditions.

Overdose and Emergency Response

Duofer Fol Overdose and When to Seek Help

Overdose with Duofer Fol, primarily due to its iron components, is classified by regulatory authorities as potentially severe and life-threatening. Accidental overdose of iron-containing products is the leading cause of fatal poisoning in children younger than 6 years of age.

Documented Overdose Manifestations

Initial overdose symptoms often include severe and persistent gastrointestinal distress such as vomiting, abdominal pain, and diarrhea. Signs of serious internal damage, such as hematemesis (vomiting blood) or melena (bloody stools), may be present. If systemic toxicity develops, symptoms can progress to lethargy, signs of shock (e.g., hypotension), metabolic acidosis, seizures, coma, or hepatic necrosis.

Immediate Actions and Treatment

Immediate medical attention must be sought for any suspected overdose. Regulatory documents mandate contacting a Poison Control Center or emergency services right away, particularly for an ingestion of 40 mg/kg of elemental iron. Treatment protocols involve symptomatic and supportive treatment, including IV fluid resuscitation and continuous monitoring. For severe, systemic toxicity, the specific chelating agent, Deferoxamine, is utilized as the established antidote. Hospitalization is required for close observation, including monitoring of serum iron concentrations and potentially an abdominal X-ray to check for unabsorbed tablets.

Therapeutic Uses of Duofer Fol

Main Uses of Duofer Fol

Duofer Fol is a combination medication primarily used for the prevention and treatment of iron deficiency and folic acid deficiency. It is frequently indicated for individuals who have an increased physiological demand for these nutrients or who are unable to maintain adequate levels through diet alone.

Common applications include:

Iron Deficiency Anemia: Treatment of confirmed iron deficiency, where the body does not have enough iron to produce sufficient hemoglobin for red blood cells.
Pregnancy and Lactation: Supplementation during pregnancy and breastfeeding to support the increased nutritional requirements of both the mother and the developing fetus or nursing infant.
Nutritional Malabsorption: Support for individuals with conditions that impair the absorption of iron and folic acid from the gastrointestinal tract.
Recovery Periods: Use during convalescence or following blood loss where nutrient stores need to be replenished.

Benefits of Treatment

The components of Duofer Fol work together to support essential biological functions, specifically focusing on blood health and cellular growth.

Restoration of Iron Levels

Iron is a fundamental component of hemoglobin, the protein in red blood cells responsible for transporting oxygen from the lungs to the rest of the body. By addressing iron deficiency, the medication helps improve oxygenation of tissues, which can alleviate symptoms such as fatigue, weakness, and shortness of breath associated with anemia.

Support for Folic Acid Requirements

Folic acid (Vitamin B9) is vital for DNA synthesis and the formation of new cells. It plays a critical role in erythropoiesis (the production of red blood cells). In the context of pregnancy, adequate folic acid intake is essential for the healthy development of the fetal neural tube and general cellular growth.

Synergistic Action

Providing iron and folic acid in a single formulation ensures that the two most common nutritional causes of anemia are addressed simultaneously. This combined approach supports the hematopoietic system more effectively than addressing a single deficiency when multiple shortages are present.

Regulatory References

NIH MedlinePlus overview on Iron Supplements

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Duofer Fol

Duofer Fol (which contains an iron salt and folic acid) is subject to strict eligibility rules based on governmental regulatory documents to ensure safe use.

Contraindicated Populations (Must Not Use)

Hypersensitivity: Patients with known allergy to the active ingredients (ferrous fumarate, folic acid) or any excipients.
Iron Overload: Individuals with conditions like haemochromatosis or haemosiderosis (excess iron storage).
Megaloblastic Anaemia: Patients with pernicious anaemia or undiagnosed megaloblastic anaemia must not take this medicine without sufficient amounts of Vitamin B12, as folic acid can mask B12 deficiency symptoms while allowing potential neurological damage to progress.
Specific Disorders: Those with rare hereditary issues like galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption (due to excipients).

Restrictions and Special Considerations

Malignant Disease: Use is contraindicated in patients with malignant disease, unless the cancer is complicated by megaloblastic anaemia due to folic acid deficiency.
Coronary Stents: Folic acid is not routinely used in patients who have received coronary stents.
Children: Eligibility is generally for adults and children over 1 year, with specific weight-based dosing provided for children up to 1 year of age.
Drug Timing: Patients taking antacids or cholestyramine require special administration timing (e.g., separating doses by at least two hours) to prevent reduced absorption of the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information identifies specific interaction patterns for Duofer Fol, primarily related to the physicochemical properties of the iron component and the metabolic activity of Folic Acid.

Interaction Classifications

Contraindicated Combination: Co-administration with Dimercaprol is prohibited due to the risk of enhanced nephrotoxicity, as documented in regulatory monographs.
Folic Acid Restriction: Folic acid, particularly in doses exceeding 0.1 mg, is restricted in cases of undiagnosed pernicious anemia to prevent obscuring the hematologic diagnosis while neurological symptoms progress.

Exposure-Modifying Substances and Timing Rules

The iron component reduces the absorption of numerous medicinal products through chelation, necessitating administration timing separation to preserve drug efficacy.

Interacting Product Category	Example Medicines	Required Separation (Iron)
Thyroid Hormones	Levothyroxine	At least 4 hours apart
Antacids / Acid Reducers	Cimetidine, Omeprazole	At least 2 hours apart
Fluoroquinolone Antibiotics	Ciprofloxacin, Ofloxacin	Separation required
Bisphosphonates	Alendronate, Risedronate	Separation required

Pharmacodynamic Interactions: Iron may reduce the effectiveness of Methyldopa and Chloramphenicol may interfere with the physiological utilization of iron.
Food and Supplements: Iron absorption is significantly reduced by compounds in tea, coffee, and dairy products, as well as by co-administered Calcium and Zinc supplements. Alcohol may reduce Folic Acid absorption.

Mechanism of Action

How Duofer Fol Works

Iron’s Role in Oxygen-Carrying Capacity

This component works through substrate delivery, supplying ferrous iron which is essential for synthesizing hemoglobin in developing red blood cells (erythroid precursors). Hemoglobin is the protein responsible for binding and transporting oxygen. This mechanistic domain directly increases the concentration of functional hemoglobin, thereby increasing the potential for oxygen binding and transport throughout the body.

Folic Acid's Role in DNA Synthesis and Cell Maturation

The folic acid component acts as a cofactor in the one-carbon metabolism pathway. This action is critical for creating the DNA building blocks required for the rapid and accurate cell division of blood cell precursors in the bone marrow. This mechanism ensures the proper, complete maturation of the red blood cells, which is required for the integrity of the erythropoiesis process.

Synergistic Effect on Blood Cell Integrity

The drug's overall effect stems from the interdependent synergy between its two components. While iron provides the functional core (hemoglobin), folic acid provides the essential DNA infrastructure for cell production. This combined approach engages the entire erythropoiesis cascade, resulting in the production of mature, circulating red blood cells with maximal hemoglobin content.

Dosage and Administration Information

Official Administration Guidelines

Duofer Fol is an oral preparation intended for administration as a film-coated tablet. The official dosing regimen is determined by the goal of use. For the prevention (prophylaxis) of concurrent iron and folate deficiency, the usual administration is one tablet once daily. For the treatment of established deficiency, the labeled dose is typically one to two tablets per day, with the final amount determined by the patient's specific iron status.

The tablet must be swallowed whole and is not to be chewed. Administration is guided by absorption principles: iron is best absorbed on an empty stomach, such as when taken before breakfast. Taking the dose with food is an administration adjustment that may mitigate gastrointestinal discomfort, but it is associated with a reduction in the rate of iron uptake.

Frequency and Course Duration

A key procedural constraint involves the duration of treatment. The regimen must extend beyond the point where initial symptoms resolve or hemoglobin levels normalize. Treatment is specifically prescribed to continue for approximately one month after hemoglobin has been fully normalized in order to ensure that the body’s iron storage reserves are replenished. The total duration of treatment should generally not exceed six months.

Special administration rules confirm that the prevention dose of one tablet daily is the officially recognized regimen for use by women before, during, and after pregnancy.

Recent Clinical Evidence

Duofer Fol: Recent Clinical Evidence

Evidence for Correcting Nutritional Anemia in Pregnancy

Clinical evaluation of the iron and folic acid combination was studied for primarily through short-term Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These studies were applied in research contexts involving pregnant women, often in the second trimester, who had an established diagnosis of iron deficiency anemia. The research explored how symptoms change over time by tracking shifts in specific blood measurements, such as Hemoglobin concentration and Ferritin levels, to assess changes in iron status.

Research highlights patterns measured during the study period. The observed data included measurements of Hemoglobin concentration in groups receiving the combination therapy versus other study groups, such as those receiving iron alone. Findings describe observed patterns related to changes in the hematological markers associated with anemia over the short term. However, the reported outcomes were primarily focused on short-term hematological changes, with typical follow-up periods around two to three months.

Evidence for Prevention (Prophylaxis) During Pregnancy

The research base for preventing nutritional deficiencies during pregnancy includes Cochrane Systematic Reviews and large-scale clinical trials. These studies were focused on pregnant women who were non-anemic at the study outset. Research examined outcomes monitoring physiological strain or stress, specifically by measuring the incidence rates of maternal anemia and iron deficiency across the full antenatal period. Findings indicate patterns related to the maintenance of nutritional status during periods of high physiological stress.

Evidence in Special Clinical Contexts and Research Durability

Research has explored the use of iron and folic acid combination therapy in other defined clinical groups, including the treatment of anemia in the postpartum period (following childbirth). Studies monitored how symptoms evolved in the observed populations across short follow-up periods, typically lasting 4 to 6 weeks. However, outcomes related to physical discomfort and fatigue were not consistently distinguished when compared to iron-only supplementation in some research.

Evidence Gaps and Areas of Uncertainty

The research highlights what is known — and what is still uncertain. The research landscape primarily consists of studies with limited follow-up durations. The available evidence does not fully establish whether the changes measured during the short study periods are sustained over extended time intervals. Data for certain groups remain insufficient, and comparative evidence is lacking, particularly between the dual-iron component in Duofer Fol and other common iron preparations. The certainty remains low in certain areas due to substantial variability across studies.

Key Studies & References

Guideline: Daily Iron and Folic Acid Supplementation in Pregnant Women (2012)

Frequently Asked Questions (FAQ)

Common questions about Duofer Fol (FAQ)

Q: Is Duofer Fol considered a vitamin supplement or a prescription medication?

Official classification can vary. Regulatory bodies categorize iron and folic acid products based on the specific dose and concentration, sometimes defining them as a prescription-only product and sometimes as an over-the-counter (OTC) dietary supplement. The specific marketing status of Duofer Fol is described in detail on the official regulatory label or package insert.

Q: How long does it usually take to see effects from Duofer Fol based on research?

Official information indicates that the body begins using the iron to produce new red blood cells within about 4 to 10 days of starting the medicine. However, achieving substantial improvement in blood tests typically takes 2 to 4 months of consistent use. Therefore, an immediate change in symptoms is generally not anticipated.

Q: What is the difference between ferrous fumarate and ferrous sulfate in iron supplements?

The primary difference between various iron salts like ferrous fumarate and ferrous gluconate (found in Duofer Fol) and ferrous sulfate is the amount of elemental iron they contain by weight. Regulatory documents define these percentages. The specific formulation of Duofer Fol utilizes two different iron salts to provide the bivalent iron required for blood cell formation, as defined by official standards.

Q: Is there any evidence that Duofer Fol affects mood or energy levels?

While the medicine is intended to correct anemia, which often involves symptoms like fatigue, the official safety documentation for the components generally does not list changes in mood, such as anxiety or depression, as common adverse effects. The intended effect of the medicine is to increase oxygen-carrying capacity, which is generally associated with potential improvements in energy.

Q: Is there a risk of iron overload when taking Duofer Fol as prescribed?

Official safety warnings advise that iron-containing medicines carry a risk of iron accumulation, or iron overload, even when taken as directed. Regulatory documents outline that professional monitoring of blood iron levels may be recommended throughout the course of treatment to prevent excessive iron buildup in the body.

Q: Does Duofer Fol contain any common allergens like gluten or lactose?

The active ingredients are generally synthetic, but the final product contains excipients, which are inactive ingredients used in manufacturing. Official regulatory labels confirm that specific formulations may contain substances like lactose or other ingredients that certain patients must avoid due to rare hereditary issues. For specific allergen concerns like gluten or lactose, the full ingredient list is available on the official package insert.

Q: Does Duofer Fol interact with common over-the-counter pain relievers?

Official drug interaction information indicates that the folic acid component is generally recognized as compatible with common pain relievers like Paracetamol (acetaminophen). However, regulatory documents note that combining the iron component with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as Ibuprofen, may carry a potential risk of increased gastrointestinal irritation.

Q: Can people with kidney issues use Duofer Fol according to official guidelines?

Regulatory guidelines recognize that oral iron and folic acid are frequently used to manage anemia associated with Chronic Kidney Disease (CKD). However, the official use is highly dependent on the severity and stage of the individual's kidney condition. The determination of the medicine’s use in this population is made by a specialized medical professional.

Q: Are there official recommendations regarding Duofer Fol use by breastfeeding individuals?

Official regulatory summaries have examined the use of oral iron and folic acid during lactation. They indicate that oral iron supplementation is generally not expected to significantly alter the iron content in breast milk or pose a notable risk of harm to the breastfed child.

Q: Can vegetarians or vegans use Duofer Fol if they are deficient? (Eligibility clarification)

The active medicinal ingredients, which are iron salts and folic acid, are generally synthetic and not derived from animal products. However, the final suitability for vegetarians or vegans depends on the source of the inactive ingredients (excipients) used in the coating or capsule shell during manufacturing. This specific information is described on the detailed product label.

Q: Is it normal to feel no immediate change after starting Duofer Fol?

Yes, based on the kinetics of red blood cell production, feeling no immediate change in symptoms is normal. The body requires several weeks to produce a sufficient number of healthy red blood cells; improvement in blood markers is generally not observed until after 2 to 4 months of treatment.

Q: What is the shelf life of Duofer Fol tablets/capsules?

The stability of the medicine is determined by the manufacturer through formal studies, which define the product's shelf life. This date is clearly indicated as the expiration date printed on the original packaging. The product's stability is maintained until this date, provided it is stored according to the official requirements (e.g., kept tightly closed and below 25 C).

Q: Can Duofer Fol affect the results of any common medical tests?

Official safety warnings state that iron-containing medicines may cause interference with certain laboratory diagnostic tests. Specifically, there is documented potential for the medicine to affect the fecal occult blood test, which is used to check for blood in the stool. This interference could lead to an inaccurate (false) test result.

Q: Is there an official monograph or package insert available for Duofer Fol?

Regulatory rules require that all prescription and over-the-counter medicines sold have an officially approved patient information leaflet, or monograph, available to the public. This document contains detailed information on use, safety, and side effects.

Q: What happens if I forget to take a dose of Duofer Fol?

Official patient instructions regarding a missed dose indicate that the dose may be taken as soon as the lapse is remembered. However, if the time is close to the next scheduled dose, the regulatory standard specifies that the missed dose should be skipped, and the regular schedule resumed.

How should Duofer Fol be stored and disposed of?

How to Store and Dispose of Duofer Fol?

Official regulatory documents define specific requirements for the storage, handling, and disposal of this medicine, which contains ferrous sulfate.

Storage Requirements

To ensure product stability, Duofer Fol must be stored in its container with the lid tightly closed and maintained at a temperature not exceeding 25 C. This is classified as a room temperature constraint.

Pediatric Safety and Disposal

It is a mandatory precaution to keep this medicine out of the sight and reach of children at all times, as an overdose of ferrous sulfate can be fatal. Regarding disposal, official documentation indicates there are no special requirements. Therefore, disposal should adhere to standard local regulatory practices for pharmaceutical waste.

Duofer Fol